Extension of previous funding round brings total raised to £7 million GBP (circa $9.2 million USD) with investment from Calculus Capital, Par Equity, and Scottish Enterprise. Funding will support continued development of Axol’s human iPS cell lines and reagents, and expansion of its commercial team

Axol Bioscience is a significant UK Partner in the Platforma initiative.

Axol Bioscience is looking for an individual who has the same passion for science as we have, as we develop new innovate products and solutions for the fields of drug discovery, toxicology and life sciences.  This is a unique opportunity to manage, lead and mentor a team of junior scientists and technicians in the expanding scientific operations team, as well as developing as an individual and contribute to Axol’s continued success. 

Axol Bioscience Expanding Account Management Team in the US

Axol Bioscience today announced the expansion of its service offering, with the introduction of multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells. The new services have been developed to support pre-clinical research by optimizing hiPSC-derived cell culture, while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models.

Cambridge, UK, 26 August 2020: Axol Bioscience, a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, today announced the appointment of Liam Taylor as CEO. Liam will guide the growth of the Company, and will focus on maximizing the potential of the team, and its iPSC (induced pluripotent stem cell) technologies, products and services.

✓ Our Booth #760
✓ Our Workshop (find out more)
✓ Our Poster (find out more)

Cambridge, UK – (6th December 2018) – Axol Bioscience, the human cell culture specialist, is launching a new line of Human induced Pluripotent Stem Cells (iPSC)-derived Microglia for the consistent and reproducible study of neuroglia and their involvement in neurodegenerative diseases, including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.

Axol Bioscience is presenting at the two-day seminar hold by Evercyte and Altetox in Vienna, from 30-31 October. Book your ticket today.

We are delighted to announce plans to open a new operational hub in the United States. The site will open in the fall of 2018 and will help to support Axol’s customer base in the United States and Canada.

Cambridge, UK – (17th July 2018) – Axol Bioscience, the human cell culture specialists, provide highly validated primary cells and iPSC-derived cells together with optimised media and growth supplements, launch their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease.

Axol Bioscience is meeting Metrion Biosciences for a whole day stem cell event, on May 23, 2018. Don't miss the opportunity to see some excellent scientific presentations.

Our team has spent the first few months of 2018 working hard to introduce an exciting new range of products to the Axol catalog. As well as the Primary and iPS derived human cells Axol is know for; we can now offer researchers the convenience of sourcing antibodies, kits and other reagents in one place.

We are attending the ELRIG Research & Innovation Meeting 2018 in Cambridge, UK, from 17-18 April 2018. We will be available throughout the conference at booth 7, during our Spotlight Sessions about Microglia and Neural Cells as well as our Poster. Join us!

We are attending the SOT Annual Meeting 2018 in Texas, from 11-15 March 2018. We will be available throughout the conference at booth 760 as well as in our workshop, March 12. Join us!

Since a funding injection by our investors in 2017, we have been working hard to double our manufacturing capacity and bring some exciting new products to market. Cells will always be the (beating) heart of what we do at Axol, but we know that until now our customers have had to look elsewhere for antibodies, kits and other reagents.